SEO URLwww.firestrike.ai/deals/rallybio-candid-therapeutics-merger-2026
mergerAnnounced · May 4, 2026biotechnologySource · CredibleArticle · Factual
Candid Therapeutics merges with Rallybio
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$50M
Party A
Rallybio
NASDAQ: RLYB · New Haven, Connecticut
Party B
Candid Therapeutics
Terminated
Status
Terminated
Candid Therapeutics and Rallybio are pursuing a merger. Reported scale / consideration: $50M. Status: Terminated. Sector: biotechnology. Target headquarters context: New Haven, Connecticut, United States.
This page summarizes publicly available information about the transaction as of 2026-05-04. Figures and status may change as filings and press coverage update.
In a regulatory filing, Rallybio said Candid Therapeutics Inc. ended the merger agreement May 3 in connection with entering into an alternative transaction with UCB S.A., a Belgian biopharmaceutical company
Deal timeline
Announced
May 4, 2026 · hartfordbusiness.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology with a reported deal value of $50M. Figures and status may change as sources update.
Sources: hartfordbusiness.com · Primary article · FireStrike proprietary index